Interim safety results of a study investigating the combination of CAR T therapy axicabtagene ciloleucel and atezolizumab for treatment of relapsed diffuse large b-cell lymphoma.
Interim safety results of a study investigating the combination of CAR T therapy axicabtagene ciloleucel and atezolizumab for treatment of relapsed diffuse large b-cell lymphoma.